IMBRUVICA ® (ibrutinib) Approved by FDA for Marginal Zone Lymphoma (MZL) Patients Who Require Systemic Therapy and Have Received At Least One Prior Anti-CD20-Based Therapy

First therapy specifically indicated for this rare blood cancer; represents fifth indication for IMBRUVICA in the U.S.
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news